Sign In
  • A-
  • A
  • A+
  • ع
  • A-
  • A
  • A+
  • ع
Prof.Azzam A. Magazachi Dean Assistant Academic RankProfessor

Specialization:

  • Immunology

Research Interests:

  • Cancer Immunotherapy, Autoimmune diseases, Drugs mechanisms of Action (MOA)

Contact

BSM. University of Baghdad, Iraq MS. New York University Medical Center, New York, USA PhD. University of Manitoba Medical School, Manitoba, Canada
•1988-1991 Group Leader, Biotechnology Research Centre, Canada •1991-1995 Group Leader, Ontario Cancer Institute. Associate Professor, Department of Microbiology and Immunology, University of Ottawa, Canada •1995-2005 Group Leader, University of Oslo, Norway •2005-2007 Chief Scientific Officer, Bio-Quant, Inc., San Diego, USA •2007-2015 Professor, University of Oslo, Norway •2016-Present Visiting Professor, University of Sharjah, Sharjah, UAE.
Editor: Frontiers in Immunology Special Issue: Immunodulatory effects of drugs for treatment of multiple sclerosis and other immune-related diseases. • Member of editorial board: Toxins • Member of editorial board: British Journal of Medicine and Medical Research • Member of editorial board: American Journal of Molecular Biology • Member of editorial board: World Journal of Immunology • Member of editorial board: World Journal of Experimental Medicine • Member of editorial board: World Journal of Biological Chemistry • Member of editorial board: ImmunoTargets and Therapy • Associate editor: International Journal of Medical and Clinical Research • Member of editorial board: Open Journal of Immunology • Editor: MOJ Immunology • Editor-in-chief: Advances in Neuroscience Research • Associate editor-in-chief: Frontiers in Clinical Medicine • Editorial board member: Trends in Molecular Biology • Member of editorial board: Journal of Biological Medicine
•American Society for Biochemistry and Molecular Biology •American Association of Immunologists •Society for Leukocyte Biology •FASEB •American Association for Cancer Research
1. Immunotherapy of cancer using Natural killer cells. 2. New therapeutic modalities for multiple sclerosis (MS) 3. Development of novel antibodies for treatment of MS disease.
1. Al-Jaderi Z, Maghazachi AA. A potential utilization of monomethyl fumarate and related drugs for treatment of multiple sclerosis and cancer. Frontiers in Immunology. In Press, 2016. 2. Vego H, Sand KL, Høglund RA, Fallang LE, Gundersen G, Holmøy T, Maghazachi AA. Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cell Mol Immunol. 13: 57-64, 2016. 3. Al-Jaderi Z, Maghazachi AA. Vitamin D3 and monomethyl fumarate enhance natural killer cell lysis of dendritic cells and ameliorate the clinical score in mice suffering from experimental autoimmune encephalomyelitis (EAE). Toxins 7: 4730-4744, 2015 4. Rolin J, Vego H, Maghazachi AA. Oxidized lipids and lysophosphatidylcholine induce the chemotaxis, up-regulate the expression of CCR9 and CXCR4 and abrogate the release of IL-6 in human monocytes. Toxins (Basel). 6: 2840-2856. doi: 10.3390/toxins6092840, 2014 5. Høglund RA, Maghazachi AA. Multiple sclerosis and the role of immune cells. World J. Exp. Med. 4: 27-37, 2014. 6. Rolin J, Maghazachi AA. Chemokine receptors and inflammatory lipids. Implications for atherosclerosis. J. Leukoc. Biol. 95: 575-585, 2014. 7. Rolin J, Maghazachi AA. Implications of chemokine receptors and inflammatory lipids in cancer. ImmunoTargets and Therapy. 3: 9-18, 2014. 8. Al-Jaderi Z, Maghazachi AA. Effects of Vitamin D3, Calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Toxins. 5: 1932-1947, 2013. 9. Sand KL, Flatebo T, Andersen MB, Maghazachi AA. Effects of exercise on leukocytosis and blood hemostasis in 800 healthy young females and males. World J. Exp. Med. 2013 3(1): 11-20, 2013. 10. Høglund R, Harbo HF, Holmøy T, Maghazachi AA. A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate. PLoS One 8(4): e62237, 2013. 11. Maghazchi AA. On the role of natural killer cells in neurodegenerative diseases. Toxins 5: 363-375, 2013. 12. Rolin J, Al-Jaderi Z, Maghazachi AA. Oxidized lipids and lysophosphatidylcholine induce the chemotaxis and intracellular calcium influx in natural killer cells. Immunobiology 218: 875-883, 2013. 13. Maghazachi AA. Role of natural killer cells in multiple sclerosis. ISRN Immunology, 2012:article ID 795075, doi:10.5402/2012/795075, 2012. 14. Troitskaya M, Baysa A, Vaage J, Sand KL, Maghazachi AA, Valen G. Interleukin-17 (IL-17) expression is reduced during acute myocardial infarction: role on chemokine receptor expression in monocytes and their in vitro chemotaxis towards chemokines. Toxins 4: 1427-1439, 2012. 15. Pandya A, Høglund RA, Holmøy T, Harbo HF, Norgauer J, Maghazachi AA. Identification of human NK17/NK1 cells. PLoS One 6(10):e26780, 2011. 16. Rolin J, Maghazachi AA. Effects of Lysophospholipids on Tumor Microenvironment. Cancer Microenvironment 4: 393-403, 2011. 17. Høglund R, Hestvik ALK, Holmøy T, Maghazazhi AA. Expression and functional activity of chemokine receptors in glatiramer acetate (GA)-specific T cells isolated from MS patient receiving the drug GA. Human Immunol. 72: 124-134, 2011. 18. Maghazachi AA. Role of chemokines in the biology of natural killer cells. Curr. Topics Microbiol. Immunol. 341: 37-58, 2010. 19. Truta-Feles K, Lagadari M, Berod L, Cubillos S, Piehler S, Herouy Y, Barz D, K, Maghazachi AA. Norgauer J.A novel role for histamine as a modulator of γδ T cell migration and cytotoxicity: invovelment of Gi and Gs protein–coupled signaling pathways. Br. J. Pharmacol. 161: 1291-1300, 2010. 20. Rolin J, Sand KL, Knudsen E, Maghazachi AA. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol. Immnuother. 59: 575-586, 2010.
1991-1995: Darren Woodside, MSc. Degree. Laurentian University, Canada. 1995-1999: Ala Al-Aoukaty, PhD degree, University of Oslo, Norway. 1998-2001: Marit Inngjerdingen, PhD degree, University of Oslo, Norway. 2001-2006: Yixin Jin, PhD degree, University of Oslo, Norway. 2003-2005: Co-supervised Devrim Oz, PhD degree, University of Marmara, Turkey, 2007-2016: Johannes Rolin, MD/PhD Student, University of Oslo, Norway. 2009-2016: Rune A. Høglund, MD/PhD Student, University of Oslo, Norway. 2011-2016: Zaidoon Al-Jaderi, PhD student, University of Oslo, Norway
MONOMETHYL- AND DIMETHYLFUMARATE FOR NK CELL ACTIVATION Inventors: MAGHAZACHI, Azzam A Application Number: EP2015/054202
•Chairman of the ”NK AND CANCER” session in the 8th annual meeting of the society of natural immunity and 20th international natural killer cell workshop (The Netherlands, 2004). •Chairman of “NK cell chemotaxis” session in 4th Nordic NK cell workshop (Norway, 2007). •Organized the 5th Framework European Community “Innate immunity and vaccine development” meeting, September 2003. •Member of the 5th EC framework consortium Innate Immunity and Vaccine Development: Role of Soluble Mediators (INVADERS). •Member of the steering committee of the 6th EC framework (CHEMCANC) program.
1. Expert in teaching PBL students. Developed several PBL tasks. 2. Taught the practical Blood course, Faculty of Medicine, to the third year medical students, University of Oslo, Norway. This course teaches students how to withdraw blood from the veins, and how to perform practical tasks such as measuring hemoglobin, PCV, MCV, hematocrit and other hematological and microbiological tests. It also teaches students how to differentially recognize and count various blood cells including neutrophils, eosinophils, monocytes, lymphocytes and basophils. 3. Taught the courses of Immunology, Microbiology and Hematology to the 3rd year medical students at the University of Oslo. Norway. 4. Taught several immunology and biochemistry courses to undergraduate students, Department of Biochemistry, Laurentian University, Canada
Back to list